Kataria S, Tandon M, Melnic V, Sriwastava S (2020) A case series and literature review of multiple sclerosis and COVID-19: clinical characteristics, outcomes and a brief review of immunotherapies
More information Positive recommendations on new generic medicines Teduglutide Viatris International non-proprietary name (INN) teduglutide Marketing authorisation applicant Viatris Limited Therapeutic indication Treatment of Short Bowel Syndrome
Both are subcutaneous injections of the same active molecule, manufactured by Novo Nordisk
Unfortunately, there is no way of knowing how a medicine will affect you until you begin to take it, but this is why GLP-1 receptor agonists are generally titrated up to the therapeutic dose over the course of several weeks, as it reduces the risk of experiencing severe or debilitating side effects
This often weakens your bone structure and increases fracture risks